Notícias de Zealand Pharma

Últimas notícias

Manchetes no idioma original da fonte.

• 
  Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026) (abre em uma nova aba)

  GlobeNewswire · 5 de out. de 2026

• 
  Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts (abre em uma nova aba)

  1 de out. de 2026

• Zealand Pharma Reports 13.1% Weight Loss in Phase 3 Survodutide Trial (abre em uma nova aba)

  MT Newswires · 1 de out. de 2026

• 
  Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes (abre em uma nova aba)

  GlobeNewswire · 1 de out. de 2026

• 
  Total number of shares and voting rights in Zealand Pharma as of September 30, 2026 (abre em uma nova aba)

  GlobeNewswire · 30 de set. de 2026

• 
  Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology (abre em uma nova aba)

  GlobeNewswire · 29 de set. de 2026

• 
  Zealand Pharma - Transactions related to share buy-back program (week 39, 2026) (abre em uma nova aba)

  GlobeNewswire · 28 de set. de 2026

• 
  Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity (abre em uma nova aba)

  GlobeNewswire · 22 de set. de 2026

• 
  Zealand Pharma - Transactions related to share buy-back program (week 38, 2026) (abre em uma nova aba)

  GlobeNewswire · 21 de set. de 2026

• 
  Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome (abre em uma nova aba)

  GlobeNewswire · 18 de set. de 2026

• 
  Zealand Pharma (CPSE:ZEAL) Grants Exclusive Type 1 Diabetes Peptide License (abre em uma nova aba)

  Simply Wall St. · 18 de set. de 2026

• Elvinix Secures Exclusive License to Advance Novel Peptide Therapy Aimed at Restoring Insulin Production in Type 1 Diabetes (abre em uma nova aba)

  15 de set. de 2026

• 
  Zealand Pharma - Transactions related to share buy-back program (week 37, 2026) (abre em uma nova aba)

  GlobeNewswire · 14 de set. de 2026

• 
  Zealand Pharma increases its share capital as a result of the exercise of employee warrants (abre em uma nova aba)

  GlobeNewswire · 10 de set. de 2026

• Zealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare Conference (abre em uma nova aba)

  9 de set. de 2026

• Zealand Pharma - Transactions related to share buy-back program (week 36, 2026) (abre em uma nova aba)

  7 de set. de 2026

• Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) (abre em uma nova aba)

  2 de set. de 2026

• Royalty Pharma (RPRX) Bets $100M On A Blood Disorder Breakthrough (abre em uma nova aba)

  1 de set. de 2026

• Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) (abre em uma nova aba)

  31 de ago. de 2026

• Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (abre em uma nova aba)

  28 de ago. de 2026